Back to Authors

Roland, J. Thomas

https://orcid.org/0000-0003-1181-4651

Mayo Clinic

NYU Langone Health

Citations 14

Long-term natural history and patterns of sporadic vestibular schwannoma growth: A multi-institutional volumetric analysis of 952 patients
Marinelli, John P. , Schnurman, Zane , Killeen, Daniel E. , Nassiri, Ashley M. , Lees, Katherine A. , Lohse, Christine M. , Golfinos, John G. , Link, Michael J. , Carlson, Matthew L. , Hunter, Jacob B. , Roland, J. Thomas , Kondziolka, Douglas

Neuro-Oncology | December 28, 2021 | Volume: 24 | Issue: 8 | Pages: 1298-1306

10.1093/neuonc/noab303 Get It

Abstract Background The current study aims to characterize the natural history of sporadic vestibular schwannoma volumetric tumor growth, including long-term growth patterns following initial detection of growth. Methods Volumetric tumor measurements from 3505 serial MRI studies were analyzed from unselected consecutive patients undergoing wait-and-scan management at three tertiary referral centers between 1998 and 2018. Volumetric tumor growth was defined as a change in volume ≥20%. Results Among 952 patients undergoing observation, 622 experienced tumor growth with initial growth-free survival rates (95% CI) at 1, 3, and 5 years following diagnosis of 66% (63–69), 30% (27–34), and 20% (17–24). Among 405 patients who continued to be observed despite demonstrating initial growth, 210 experienced subsequent tumor growth with subsequent growth-free survival rates at 1, 3, and 5 years following initial growth of 77% (72–81), 37% (31–43), and 24% (18–31). Larger tumor volume at initial growth (HR 1.13, P = .02) and increasing tumor growth rate (HR 1.31; P < .001) were significantly associated with an increased likelihood of subsequent growth, whereas a longer duration of time between diagnosis and detection of initial growth was protective (HR 0.69; P < .001). Conclusions While most vestibular schwannomas exhibit an overall propensity for volumetric growth following diagnosis, prior tumor growth does not perfectly predict future growth. Tumors can subsequently grow faster, slower, or demonstrate quiescence and stability. Larger tumor size and increasing tumor growth rate portend a higher likelihood of continued growth. These findings can inform timing of intervention: whether upfront at initial diagnosis, after detection of initial growth, or only after continued growth is observed.
Iatrogenic Third Window After Retrosigmoid Approach to a Vestibular Schwannoma Managed with Cochlear Implantation
Deep, Nicholas L. , Kay‐Rivest, Emily , Roland, J. Thomas

Otology & Neurotology | July 15, 2021 | Volume: 42 | Issue: 9 | Pages: 1355-1359

10.1097/mao.0000000000003267 Get It

Objective: To present a case of an iatrogenic inner ear third window after vestibular schwannoma microsurgery. Patients: A 42-year-old male presented 9-months after left-sided retrosigmoid approach for an intracanalicular vestibular schwannoma with hearing-preservation attempt performed elsewhere. Immediately postoperatively, he developed the following disabling and persistent symptoms on the ipsilateral side: autophony, pulsatile tinnitus, high-pitched ringing tinnitus, and hearing his footsteps. He denied vertigo. Otoscopy was normal. Tuning fork (512-Hz) lateralized to the left and Rinne was negative on the left. Audiogram demonstrated a severe mixed hearing loss and 10% aided word-recognition score. High-resolution CT demonstrated violation of the common crus and dehiscence of bone along the medial vestibule suggestive of an iatrogenic inner ear third window. Interventions: Labyrinthectomy and concurrent cochlear implantation. Main outcome measures: Resolution of third window symptoms, open-set speech recognition, tinnitus suppression. Results: Patient reported immediate resolution of third window symptoms after labyrinthectomy and cochlear implantation. He demonstrates open-set word recognition of 64% at 1-year postoperatively and tinnitus suppression with his cochlear implant on. Conclusions: Iatrogenic third window symptoms can occur after hearing-preservation vestibular schwannoma microsurgery. Patients with sufficient hearing preservation who are disabled by third window symptoms yet lack sound clarity and useful hearing may be considered for labyrinthectomy and concurrent cochlear implantation. This intervention effectively extinguishes third window symptoms by destroying residual auditory function and simultaneously provides an opportunity to restore useful hearing and suppress tinnitus, thereby enhancing overall quality of life.
American Neurotology Society, American Otological Society, and American Academy of Otolaryngology – Head and Neck Foundation Guide to Enhance Otologic and Neurotologic Care During the COVID-19 Pandemic
Remenschneider, Aaron K. , Blevins, Nikolas H. , Quesnel, Alicia M. , Chari, Divya A. , Kesser, Bradley W. , Weinstein, Jaqueline E., Ahsan, Syed F. , Telischi, Fred F. , Adunka, Oliver F., Knoll, Renata M. , Coelho, Daniel H. , Anne, Samantha , Franck, Kevin H. , Barker, Frederick G., Carter, Bob S. , Lustig, Lawrence R. , Bojrab, Dennis I. , Bhansali, Sanjay A., Westerberg, Brian D. , Lundy, Larry, Jackler, Robert K. , Chandrasekhar, Sujana S. , Antonelli, Patrick J. , Carey, John P. , Slattery, William H. , Weinstein, Jacqueline E. , Jackler, Robert K , Kozin, Elliott D. , Jan, Taha Adnan , Weber, Peter C. , Marchioni, Daniele , Roland, J. Thomas , Welling, D. Bradley , Lee, Daniel J.

Otology & Neurotology | August 21, 2020 | Volume: 41 | Issue: 9 | Pages: 1163-1174

10.1097/mao.0000000000002868 Get It

This combined American Neurotology Society, American Otological Society, and American Academy of Otolaryngology – Head and Neck Surgery Foundation document aims to provide guidance during the coronavirus disease of 2019 (COVID-19) on 1) “priority” of care for otologic and neurotologic patients in the office and operating room, and 2) optimal utilization of personal protective equipment. Given the paucity of evidence to inform otologic and neurotologic best practices during COVID-19, the recommendations herein are based on relevant peer-reviewed articles, the Centers for Disease Control and Prevention COVID-19 guidelines, United States and international hospital policies, and expert opinion. The suggestions presented here are not meant to be definitive, and best practices will undoubtedly change with increasing knowledge and high-quality data related to COVID-19. Interpretation of this guidance document is dependent on local factors including prevalence of COVID-19 in the surgeons’ local community. This is not intended to set a standard of care, and should not supersede the clinician's best judgement when managing specific clinical concerns and/or regional conditions. Access to otologic and neurotologic care during and after the COVID-19 pandemic is dependent upon adequate protection of physicians, audiologists, and ancillary support staff. Otolaryngologists and associated staff are at high risk for COVID-19 disease transmission based on close contact with mucosal surfaces of the upper aerodigestive tract during diagnostic evaluation and therapeutic procedures. While many otologic and neurotologic conditions are not imminently life threatening, they have a major impact on communication, daily functioning, and quality of life. In addition, progression of disease and delay in treatment can result in cranial nerve deficits, intracranial and life-threatening complications, and/or irreversible consequences. In this regard, many otologic and neurotologic conditions should rightfully be considered “urgent,” and almost all require timely attention to permit optimal outcomes. It is reasonable to proceed with otologic and neurotologic clinic visits and operative cases based on input from expert opinion of otologic care providers, clinic/hospital administration, infection prevention and control specialists, and local and state public health leaders. Significant regional variations in COVID-19 prevalence exist; therefore, physicians working with local municipalities are best suited to make determinations on the appropriateness and timing of otologic and neurotologic care.